This entry begins with what is true, because most of the coverage on both sides gets it wrong in one direction or the other.
Prescription drug prices did fall. Bureau of Labor Statistics data released in mid-August 2026 showed them down 3.1 percent over the year, the largest one-year decline since 1963, and down 3.3 percent since January, the steepest six-month drop since BLS began tracking in 1947. The administration's most-favored-nation deals are also real: since November it has announced agreements with 17 large drug companies, including Pfizer, Merck and Johnson & Johnson, to offer certain drugs at prices comparable to other wealthy countries in exchange for three years of tariff relief. On August 31 Trump announced deals with nine more midsize biotech companies.
What FactCheck.org documented on August 31 is the gap between that record and how it is being described. Trump said on August 14 and repeated at the White House event: “For decades, Americans paid the highest prices for prescription drugs. We paid more for prescription drugs than anywhere in the world. And now we pay the lowest price anywhere in the world for prescription drugs.” That is not what the agreements do.
The agreements are narrower than the description. For existing drugs, MFN pricing applies only in limited circumstances: drugs sold to state Medicaid programs, direct-to-consumer sales through TrumpRx, and certain GLP-1 weight-loss and diabetes drugs sold to Medicare or Medicaid. They do not affect what most Americans pay, because most Americans have private insurance, which the deals leave untouched.
On causation, drug-pricing experts told FactCheck.org that neither TrumpRx nor the company agreements were likely major drivers of the decline, pointing instead to market pressure on GLP-1 weight-loss drugs, more generics entering the market, and the Biden-era policy letting Medicare negotiate prices. Cynthia Cox of KFF, which is nonpartisan: “It's totally possible that there are both some Republican policies, or, you know, Trump policies, as well as Biden policies that are at play here. But I think there's also just market forces at play, in particular around GLP-1 drugs, that are really hard to ignore.” CMS Administrator Mehmet Oz had posted the opposite: “Why did drug prices DROP? The answer: President Donald J. Trump fulfilling his promises to the American people.”
The $500 to $600 billion savings projection has its own problem. FactCheck.org examined it in June and found it rests on shaky assumptions, and a Johns Hopkins analyst said, “We've seen no indication from pharma, from other key stakeholders, that this $600 billion number is real.” A Public Citizen analysis found 16 companies from earlier rounds of the program raised list prices on 272 products in the first months of 2026.
The White House response, from spokesman Kush Desai, is on the record and is not unreasonable on its own terms: the MFN deals “cover hundreds of drugs, including GLP-1s and fertility drugs that are enormously popular and not typically covered by insurance,” and “TrumpRx.gov has already saved real patients over $700 million.” The precise version of this entry: a real policy with real but bounded effects is being described as a total transformation, its results are being claimed as caused by it when experts say other factors likely dominate, and the headline savings figure is not one the industry or independent analysts endorse (see Trump Launches TrumpRx.gov, a Government Prescription Drug Program Bearing His Name and RFK Jr. Tells Senate That Trump 'Has His Own Way of Calculating Percentages' as TrumpRx Is Found to Lower Prices on Exactly One Drug).
Update (September 25, 2026): Trump's own nominee to run the FDA would not repeat the claim. At her September 24 confirmation hearing, Sen. Bernie Sanders asked Dr. Heidi Overton, a deputy assistant to the president for domestic policy, several times whether it is true that Americans now pay the lowest drug prices in the world: “Is it true that we pay the lowest prices in the world for prescription drugs as President Trump has said?” She did not say yes. She said 89 percent of branded drugs are covered by agreements to lower prices, and that CPI shows that “for the first time in 60 years, prescription drug prices have gone down by 3%.” Sanders replied, “Yeah, which may have something to do with the legislation that we passed several years ago.” She cited the real decline; she did not affirm the claim.